Ernest Chijioke Madu

Ernest Chijioke Madu

Auto-generated profile, based on publicly available information

Ernest Chijioke Madu

Division of Cardiovascular Medicine, Heart Institute of the Caribbean and HIC Heart Hospital, Kingston, Jamaica

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RZRong Zhang
Rong Zhang
MKMichelle S C Khoo
Michelle S C Khoo
YWYuejin Wu
Yuejin Wu
YYYingbo Yang
Yingbo Yang
CGChad E Grueter
Chad E Grueter
MAMark E Anderson
Mark E Anderson

26 September 2006 in Circulation
Verified
Journal Article
Closed access
MKMichelle S.C. Khoo
Michelle S.C. Khoo
JLJingdong Li
Jingdong Li
MSMadhu V. Singh
Madhu V. Singh
YYYingbo Yang
Yingbo Yang
PKPrince Kannankeril
Prince Kannankeril
MAMark E. Anderson
Mark E. Anderson
Background—Activation of cellular Ca2+signaling molecules appears to be a fundamental step in the progression of cardiomyopathy and arrhythmias. Myocardial overexpression of the constitutively active Ca2+-dependent phosphatase calcineurin (CAN) causes severe cardiomyopathy marked by left ventricular (LV) dysfunction, arrhythmias, and increased mortality rate, but CAN antagonist drugs primarily reduce hypertrophy without improving LV function or risk of death.Methods and Results—We found that activity and expression of a second Ca2+-activated signaling molecule, calmodulin kinase II (CaMKII), were increased in hearts from CAN transgenic mice and that CaMKII-inhibitory drugs improved LV function and suppressed arrhythmias. We devised a genetic approach to “clamp” CaMKII activity in CAN mice to control levels by interbreeding CAN transgenic mice with mice expressing a specific CaMKII inhibitor in cardiomyocytes. We developed transgenic control mice by interbreeding CAN transgenic mice with mice expressing an inactive version of the CaMKII-inhibitory peptide. CAN mice with CaMKII inhibition had reduced risk of death and increased LV and ventricular myocyte function and were less susceptible to arrhythmias. CaMKII inhibition did not reduce transgenic overexpression of CAN or expression of endogenous CaMKII protein or significantly reduce most measures of cardiac hypertrophy.Conclusions—CaMKII is a downstream signal in CAN cardiomyopathy, and increased CaMKII activity contributes to cardiac dysfunction, arrhythmia susceptibility, and longevity during CAN overexpression.

1 May 1995 in Chest
Verified
Journal Article
Closed access
PDF file
AMAssad H. Mouhaffel
Assad H. Mouhaffel
EMErnest C. Madu
Ernest C. Madu
WSWendy A. Satmary
Wendy A. Satmary
TFTheodore D. Fraker
Theodore D. Fraker

1 November 2003 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
JRJeffrey N Rottman
Jeffrey N Rottman
GNGemin Ni
Gemin Ni
MKMichelle Khoo
Michelle Khoo
ZWZhizhang Wang
Zhizhang Wang
WZWei Zhang
Wei Zhang
EMErnest C Madu
Ernest C Madu

3 February 1997 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
EMErnest C. Madu
Ernest C. Madu
IDIvan A. D'CRuz
Ivan A. D'CRuz

1 October 1994 in The American Journal of Medicine
Verified
Journal Article
Closed access
BGBlair P. Grubb
Blair P. Grubb
DSDaniela Samoil
Daniela Samoil
DKDaniel Kosinski
Daniel Kosinski
DWDouglas Wolfe
Douglas Wolfe
MLMichael Lorton
Michael Lorton
EMErnest Madu
Ernest Madu